We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0M3Q market cap is 73.44B. The company's latest EPS is USD 2.7253 and P/E is 59.87.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.26B | 6.68B | 7.78B | 8.08B | 8.54B |
| Operating Income | 1.97B | 2.22B | 2.73B | 2.88B | 2.98B |
| Net Income | 1.5B | 1.64B | 2.04B | 2.11B | 2.34B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 11.55B | 13.61B | 13.9B | 14.93B | 14.29B |
| Total Liabilities | 8.84B | 9.84B | 9.36B | 10.52B | 9.3B |
| Total Equity | 2.71B | 3.77B | 4.54B | 4.4B | 4.99B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 1.8B | 2.13B | 2.21B | 1.91B | 2.35B |
| Investing | -504M | -572M | -458M | -883M | -777M |
| Financing | -951M | 123M | -1.86B | -904M | -3.11B |
| Market Cap | 73.44B |
| Price to Earnings Ratio | 59.87 |
| Price to Sales Ratio | 16.42 |
| Price to Cash Ratio | 68.76 |
| Price to Book Ratio | 28.12 |
| Dividend Yield | - |
| Shares Outstanding | 860.1M |
| Average Volume (1 week) | 15.51k |
| Average Volume (1 Month) | 17.29k |
| 52 Week Change | 0.00% |
| 52 Week High | 85.38 |
| 52 Week Low | 85.38 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Zoetis Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.zoetis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
